8-K current report · filed Nov 9, 2026

Perspective Therapeutics, Inc. (CATX) 8-K Current Report: November 9, 2026

Item 2.02Item 8.01Item EX-99.1Item EX-99.2CATX overview

Short answer

Perspective Therapeutics, Inc. (CATX) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Press release covers Q3 2026 results for quarter ended September 30, 2026.

Perspective Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Press release covers Q3 2026 results for quarter ended September 30, 2026
  • Recent business highlights accompany financial results, with details in Exhibit 99.1
  • Investor focus: quarterly performance and operational updates from Perspective Therapeutics

Item 8.01 · Other Events

  • Updated corporate presentation posted November 9, 2026, providing investors with the company’s latest strategic and business overview
  • Presentation filed as Exhibit 99.2, requiring review for updated pipeline, clinical, financing, or corporate developments

Item EX-99.1 · Exhibit EX-99.1

  • 3Q 2026 results: net loss $32.4M, or $0.27 per share, versus $26.0M and $0.35 in 3Q 2025
  • Cash, equivalents and short-term investments $202M at September 30, 2026, funding planned milestones and investments into 2028
  • VMT-α-NET Cohort 4 completed with 20 patients, supporting planned FDA end-of-Phase 2 meeting in 1Q 2027
  • VMT01 melanoma cohort reached 12 treated patients, with five added since reopening and enrollment continuing
  • PSV359 received FDA Fast Track designation, with Merck collaboration supporting potential Keytruda combination studies

Item EX-99.2 · Exhibit EX-99.2

  • Investor presentation outlines three independent clinical-stage radiopharmaceutical programs, each targeting data in 2027
  • Pipeline targets neuroendocrine tumors, melanoma, advanced solid tumors and selected medullary thyroid cancers
  • Management cites a $45 billion+ combined solid-tumor addressable market
  • Bamzireotide navoxetan, lapemelanotide zapixetar and PSV359 remain in Phase 1/2a development
  • Platform emphasizes ²¹²Pb therapies, integrated isotope production and regional manufacturing for hospital delivery

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Perspective Therapeutics, Inc. 8-K filings

Get the next CATX 8-K as it lands

Follow CATX for push alerts, or ask the research agent what this filing means.